NCT02914691View on ClinicalTrials.gov

Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 5, 2017

Study Completion Date

July 5, 2017

Conditions
Type 2 DiabetesDiabetic Nephropathy
Interventions
DRUG

Dapagliflozine 10 mg once daily tablet treatment

DRUG

Placebo identical once daily tablet treatment

Trial Locations (1)

2820

Steno Diabetes Center, Gentofte Municipality

All Listed Sponsors
lead

Peter Rossing

OTHER

NCT02914691 - Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes | Biotech Hunter | Biotech Hunter